Environmental Impact Acquisition Corp. Class A ENVI 深 沪
已收盘 02-02 16:00:00 美东时间
8.82
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.82
- 总市值 2.28亿
- 52周最高 10.12
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 8.57
- 委 比 0.00%
- 总股本 2587.50万
- 历史最高 10.12
- 量 比 0
- 振 幅 0.00%
- 历史最低 8.57
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Orano Canada and Denison Announce SABRE 1st Production at McClean Lake
SASKATOON, SK, July 17, 2025 /PRNewswire/ - Orano Canada Inc. ("Orano Canada") and Denison Mines Corp. ("Denison") (TSX: DML) (NYSE American: DNN), as joint-venture partners in the McClean L...
07-17 18:30
i-80 Gold Provides Progress Update on its New Development Plan
RENO, Nev., July 8, 2025 /PRNewswire/ - i-80 GOLD CORP. (TSX: IAU) (NYSE American: IAUX) ("i-80" or the "Company") is pleased to provide an update on the progress of its new development plan...
07-08 19:15
Omai Gold Mines Advances Environmental Permitting for Guyana Project
Omai Gold Mines ( ($TSE:OMG) ) has shared an update. Omai Gold Mines Corp. has ...
06-24 00:59
【爱建医药】ADA 2025蓄势待发，关注减肥药赛道
（转自：爱建证券研究所） ADA 2025 蓄势待发，关注 减肥药赛道 -爱建生物医药行业周报- 本报告发布于2025年06月17日 投资要...
06-18 10:28
DMD基因治疗报道第二例死亡，直接诱因是？
6月15日，杜氏肌营养不良症（DMD）治疗先驱Sarepta再次更新了该公司已上市基因疗法ELEVIDYS（研发代码：SRP-9001）的安全信息。 ELEV...
06-16 12:50
Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week
UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase.
06-14 02:42
FDA Approves UroGen's ZUSDURI For Intravesical Solution As Medication For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent tumor ablation delivered by innovative RTGel® technology.Approval supported by pivotal Phase 3 ENVISION trial demonstrating 78% of
06-13 01:29
UroGen Pharma Announces Results From ENVISION And ATLAS Clinical Studies Exploring Investigational Therapy UGN-102 For Intravesical Solution For Treatment For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Presents 18-month duration of response (DOR) data from the ENVISION studyAnalyzes the impact of tumor burden or focality in recurrent LG-IR-NMIBC, a substudy from ENVISIONReports ENVISION and ATLAS complete response and
06-02 22:01
Aclara Resources Advances Carina Project with EIA Submission
An announcement from Aclara Resources, Inc. ( ($TSE:ARA) ) is now available. Ac...
05-29 19:50
